Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Senators Ask CMS To Pause Biosimilar Payment Rule

This article was originally published in Scrip

Executive Summary

A group of 20 US senators on Oct. 8 asked the Centers for Medicare & Medicaid Services (CMS) to postpone its proposed rule, which seeks to lump biosimilars referenced on the same innovator into the same Medicare Part B reimbursement rate, until after the FDA has completed its regulations and the pipeline and the market for the products are "safe and stable."



Related Companies